Table 2.
Reported cases of Graves’ disease after exposure to SARS-CoV-2 vaccination
| Our case | Pfizer (n = 32) |
Moderna (n = 6) |
Pfizer and Moderna (n = 50) |
AstraZeneca (n = 10) |
Johnson & Johnson (n = 1) |
Sinovac (n = 1) |
|
|---|---|---|---|---|---|---|---|
| Vaccine Type | mRNA (Pfizer) | mRNA | mRNA | mRNA | Viral vector | Viral vector | Inactivated |
| Age, year | 41 | 44.8 (22–74) | 45.8 (36–63) | 43.4 (22–74) | 43.3 (19–70) | 68 | 44 |
| Male, n (%) | Female | 9 (28) | 2 (33) | 12 (24) | 3 (30) | Female | Female |
| Time of symptom onset after vaccination, day | 14 | 18.5 (1–120) | 16.3 (2–46) | 18.7 (1–120) | 13.2 (2–31) | 32 | 7 |
| Dose, n (%) | Second |
First 21 (66) Second 10 (31) Third 1 (3) |
First 3 (50) Second 3 (50) |
First 29 (58) Second 20 (40) Third 1 (2) |
First 9 (90) Second 1 (10) |
First | First |
| Enlarged thyroid, n (%) | No | 18/24 (75) | 2/4 (50) | 32/40 (80) | 1/8 (13) | NA | NA |
| Relapse, n (%) | No | 4 (13) | 1/5 (20) | 11/49 (22) | 2 (20) | No | Yes |
| FT3, pmol/L | 33.2 | 19.8 (7.8–44.1) | 27.5 (n = 1) | 21.3 (6.3–44.1) | 30.7 (n = 1) | 21.2 | 14.8 |
| FT4, pmol/L | 72.1 | 48.4 (21–108) | 50.4 (20–77) | 48.2 (14–108) | 43.7 (29–61) | 46.3 | 34.4 |
| Positive Tg-Ab, n (%) | Yes | 14/22 (64) | 3/4 (75) | 17/26 (65) | 3/3 (100) | NA | Yes |
| Positive TPO-Ab, n (%) | Yes | 17/26 (65) | 5/5 (100) | 22/31 (71) | 7/8 (83) | Yes | Yes |
mRNA messenger RNA, FT3 free triiodothyronine, FT4 free thyroxine, Tg-Ab thyroglobulin antibody, TPO-Ab thyroid peroxidase antibody, NA not available